FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| (II | IE2 | AND EXCHANGE | COMMISSIO |
|-----|-----|--------------|-----------|
| | | | |

| OMB APPRO | JVAL |
|------------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average bure | den |
| hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Radhakrishnan Anup | | | | | | | 2. Issuer Name and Ticker or Trading Symbol CARGO Therapeutics, Inc. [CRGX] | | | | | | | | all application of the contraction of the contracti | r 10% Owne (give title Other (spec | | vner | | | |
|--|---|------------|----------------------------|---------|------------------------------|---|---|-------------------------|-----------------------------|---------------|---|---|--|--|--|--|-------------------------------------|--|--|--|--|
| (Last) (First) (Middle) C/O CARGO THERAPEUTICS, INC. 835 INDUSTRIAL ROAD, SUITE 400 | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 09/18/2024 | | | | | | | | | Officer (give title Other (specify below) Chief Financial Officer | | | | | | |
| (Street) SAN CARLOS CA 94070 (City) (State) (Zip) | | | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | | | ion | 2A. Deemed Execution Date, | | 3. 4. Se | | 4. Securities | SPOSED OT, OF BENETIC Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and | | | 5. Amor Securit Benefic Owned | | Form (D) o | n: Direct r Indirect istr. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | 1 | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | | | |
| Common | Stock | | | 09/18/2 | 024 | !4 | | M | | 1,600 | A | \$5.03 | 5.03 8 | | 8,046 | | D | | | | |
| Common Stock 09/18/202 | | | | | 024 | !4 | | S ⁽¹⁾ | | 1,600 | 1,600 D \$25.2 | | 2825 ⁽²⁾ 6,446 | | 446 | | D | | | | |
| | | T | able I | | | | | | | | sposed of , converti | | | y Ow | ned | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | | if any (Month/Day/Year) | | 4. Transa Code (8) | | | | 6. Date Expira (Month | tion D | | 7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4) | | | | 9. Number derivative Securities Securities Geneficiall Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exerci | sable | Expiration Date | Title | Amount or Number of Shares | | | | | | | | |
| Stock Option (Right to Buy) | \$5.03 | 09/18/2024 | | М | | | | 1,600 | (3 | 3) | 04/20/2033 | Common Stock | 1,600 | 00 \$0 53,180 | | | D | | | | |

Explanation of Responses:

- 1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 28, 2024.
- 2. This transaction was executed in multiple trades in prices ranging from \$25.25 to \$25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 3. 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

/s/ Halley Gilbert, as attorney-

in-fact for Anup 09/20/2024

Radhakrishnan

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.